Clinical trial
Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal…
NCT00054873 · Chiron Corporation, Industry · Completed
Key facts
| NCT number | NCT00054873 |
|---|---|
| Title | Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer |
| Lead sponsor | Chiron Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Neoplasms, Stomach Neoplasms, Adenocarcinoma |
| Intervention type | Drug |
| Interventions | tezacitabine, 5-fluorouracil |
| Start date | Nov 1, 2003 |
| Completion | Dec 1, 2004 |
| First posted | Feb 13, 2003 |
| Last update posted | Jul 11, 2006 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: